» Articles » PMID: 11027188

Computational Model for Effects of Ligand/receptor Binding Properties on Interleukin-2 Trafficking Dynamics and T Cell Proliferation Response

Overview
Journal Biotechnol Prog
Date 2000 Oct 12
PMID 11027188
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Multisubunit cytokine receptors such as the heterotrimeric receptor for interleukin-2 (IL-2) are ubiquitous in hematopoeitic cell types of importance in biotechnology and are crucial regulators of cell proliferation and differentiation behavior. Dynamics of cytokine/receptor endocytic trafficking can significantly impact cell responses through effects of receptor down-regulation and ligand depletion, and in turn are governed by ligand/receptor binding properties. We describe here a computational model for trafficking dynamics of the IL-2 receptor (IL-2R) system, which is able to predict T cell proliferation responses to IL-2. This model comprises kinetic equations describing binding, internalization, and postendocytic sorting of IL-2 and IL-2R, including an experimentally derived dependence of cell proliferation rate on these properties. Computational results from this model predict that IL-2 depletion can be reduced by decreasing its binding affinity for the IL-2R betagamma subunit relative to the alpha subunit at endosomal pH, as a result of enhanced ligand sorting to recycling vis-à-vis degradation, and that an IL-2 analogue with such altered binding properties should exhibit increased potency for stimulating the T cell proliferation response. These results are in agreement with our recent experimental findings for the IL-2 analogue termed 2D1 [Fallon, E. M. et al. J. Biol. Chem. 2000, 275, 6790-6797]. Thus, this type of model may enable prediction of beneficial cytokine/receptor binding properties to aid development of molecular design criteria for improvements in applications such as in vivo cytokine therapies and in vitro hematopoietic cell bioreactors.

Citing Articles

Engineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity.

Leonard E, Tomala J, Gould J, Leff M, Lin J, Li P JCI Insight. 2024; 9(18).

PMID: 39115939 PMC: 11457862. DOI: 10.1172/jci.insight.173469.


Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model.

Piranfar A, Moradi Kashkooli F, Zhan W, Bhandari A, Saboury B, Rahmim A NPJ Syst Biol Appl. 2024; 10(1):39.

PMID: 38609421 PMC: 11015041. DOI: 10.1038/s41540-024-00362-4.


A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models.

Efe O, Gassen R, Morena L, Ganchiku Y, Al Jurdi A, Lape I J Clin Invest. 2024; 134(5).

PMID: 38426492 PMC: 10904054. DOI: 10.1172/JCI173107.


A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats.

Nguyen L, Li Z, Yan X, Krzyzanski W J Pharmacokinet Pharmacodyn. 2021; 48(5):687-710.

PMID: 34100188 DOI: 10.1007/s10928-021-09762-z.


Modeling cell-specific dynamics and regulation of the common gamma chain cytokines.

Farhat A, Weiner A, Posner C, Kim Z, Orcutt-Jahns B, Carlson S Cell Rep. 2021; 35(4):109044.

PMID: 33910015 PMC: 8179794. DOI: 10.1016/j.celrep.2021.109044.